{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$7.55B vs. cons $7.37B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Yeztugo (lenacapavir PrEP) Sales (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$300M vs. cons $260M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Trodelvy Sales (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$460M vs. cons $438M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Total Product Sales Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$30.4B-$30.8B vs. cons $30.2B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Yeztugo Sales Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$1.1B-$1.2B vs. cons $1.0B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Underlying (ex-IPR&D charge) Non-GAAP EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$8.40-$8.60 (implied ex-charge) vs. cons $8.45 (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY2026 HIV Franchise Growth Guidance",
      "prediction": "BETTER",
      "answer": "guide ~8%-9% vs. cons ~8% (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Headline GAAP/non-GAAP EPS loss (~$7/share, already flagged and priced by sophisticated holders) is one-time IPR&D noise, so the market should look through it to a base-business beat (revenue, Yeztugo acceleration, Trodelvy post-approval launch strength) plus a raised FY product-sales and Yeztugo guide; as sell-side models get rebuilt ex-charges over the following days, price targets and estimates should be revised up rather than trimmed, supporting continued buying rather than a fade. Residual risk is that mainstream/retail reaction to the giant GAAP loss headline causes an initial overreaction that needs a day or two to reverse, but underlying fundamentals (HIV durability to 2036, Trodelvy label expansion, imminent BIC/LEN PDUFA, favorable CA Supreme Court ruling) argue for follow-through rather than fade over the week.",
  "day5_confidence": "LOW"
}